Continuum Advisory, LLC Novavax Inc Transaction History

Continuum Advisory, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Dec 13, 2023	SELL	$8.86 - $25.04 $1,107 - $3,130	-125 Reduced 0.55%	22,600 $232,000
Q4 2022 Feb 10, 2023	SELL	$8.86 - $25.04 $1,107 - $3,130	-125 Reduced 0.55%	22,600 $232,000
Q1 2022 Dec 13, 2023	BUY	$69.73 - $142.9 $8,716 - $17,862	125 Added 0.55%	22,725 $1.67 Million
Q1 2022 May 17, 2022	BUY	$69.73 - $142.9 $8,716 - $17,862	125 Added 0.55%	22,725 $33,000
Q4 2021 Dec 13, 2023	SELL	$134.56 - $217.97 $1,345 - $2,179	-10 Reduced 0.04%	22,600 $3.23 Million
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $1,345 - $2,179	-10 Reduced 0.04%	22,600 $37,000
Q3 2021 Dec 13, 2023	BUY	$177.8 - $270.58 $1,778 - $2,705	10 Added 0.04%	22,610 $4.69 Million
Q3 2021 Nov 08, 2021	BUY	$177.8 - $270.58 $4.02 Million - $6.12 Million	22,610 New	22,610 $45,000

292

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $629M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Continuum Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Continuum Advisory, LLC with notifications on news.